A randomized, controlled study of autologous therapy with bone marrow–derived aldehyde dehydrogenase bright cells in patients with critical limb ischemia
Catheterization and Cardiovascular Interventions2011Vol. 78(7), pp. 1060–1067
Citations Over TimeTop 10% of 2011 papers
Emerson C. Perin, Guilherme Silva, Amir Gahremanpour, John Canales, Yi Zheng, Maria G. Cabreira‐Hansen, Farrell O. Mendelsohn, Nicolas Chronos, Rebecca Haley, James T. Willerson, Brian H. Annex
Abstract
Administration of autologous ALDH(br) cells appears to be safe and warrants further study in patients with CLI.
Related Papers
- → Advances in Endovascular Treatment of Critical Limb Ischemia(2011)23 cited
- → Angiosome-Guided Intervention in Critical Limb Ischemia(2017)10 cited
- → Cost-Efficacy Issues in the Treatment of Peripheral Vascular Disease: Primary Amputation or Revascularization for Limb-threatening Ischemia(1995)35 cited
- → Patients with critical limb ischemia (CLI) not suitable for revascularization(2021)2 cited
- → Timing of Minor Amputation Following Lower Extremity Revascularization Impacts Healing Outcomes(2019)